Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of Lovaza® in Acute Myocardial Infarction (OmegaMI)

This study has been terminated.
(Only 5 individuals were able to be recruited.)
Sponsor:
Collaborators:
GlaxoSmithKline
Albany College of Pharmacy and Health Sciences
Information provided by (Responsible Party):
Robert Block, University of Rochester
ClinicalTrials.gov Identifier:
NCT01155336
First received: June 25, 2010
Last updated: March 8, 2013
Last verified: March 2013

June 25, 2010
March 8, 2013
June 2010
May 2011   (final data collection date for primary outcome measure)
Platelet Function [ Time Frame: 12 hours ] [ Designated as safety issue: No ]
Platelet function will be measured with PFA-100 test which has been shown to correlate with an increased risk for cardiovascular events in several well conducted studies and in a meta-analysis. The PFA-100 measures the number of seconds required for a clot to form in whole blood which is passed through an aperture in a cartridge coated with epinephrine. It is meant to imitate clotting in human arteries.
Platelet Function [ Time Frame: 12 hours ] [ Designated as safety issue: No ]
Platelet function will be measured with PFA-100 test which has been shown to correlate with an increased risk for cardiovascular events in several well conducted studies and in a meta-analysis.
Complete list of historical versions of study NCT01155336 on ClinicalTrials.gov Archive Site
Cardiac Electrophysiology [ Time Frame: 1 week ] [ Designated as safety issue: No ]
A 20-minute supine 12-lead Holter ECG will allow the quantification of a series of standard ECG parameters as well as provide insight into frequency-domain HRV parameters, QRS duration and morphology, using signal-averaged ECG (SAECG), repolarization morphology, and variability utilizing specialized programs.
Same as current
Not Provided
Not Provided
 
The Effects of Lovaza® in Acute Myocardial Infarction
The Effects of Lovaza® on Platelet Function and Cardiac Electrophysiology in Acute Myocardial Infarction

This study will explore the safety and effectiveness of adding Lovaza® to the therapeutic program utilized internationally for the treatment of individuals with acute coronary syndromes.

Atherosclerotic cardiovascular disease is the cause for over 19 million deaths in the US annually with coronary artery disease accounting for most of this mortality burden.1 Despite major advances in the treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. For those who arrive alive at an emergency department, a benefit is accrued from an orchestrated program of live-saving therapeutics designed to preserve ischemic or infarcted myocardium and prevent ventricular arrhythmias. However, despite improvements in door-to-balloon (angioplasty) times in the past decade, reductions in in-hospital mortality have not materialized.2 Average 30-day mortality from ST elevation MI has been shown to be approximately 7% despite the modern aggressive approach of utilizing acute pharmacologic and percutaneous interventions as well as a comprehensive approach to risk factor modification.3 Antiplatelet agents including aspirin, clopidogrel, heparin, and IIb/IIIa inhibitors represent stalwart components of the acute coronary syndrome therapeutic treatment program. At the same time, the safety of combination antiplatelet agents used acutely and chronically in individuals with an acute coronary syndrome is concerning as bleeding complications can result in serious, life-threatening consequences.4 Studies have shown that patients treated with the combination of aspirin and clopidogrel have a small but significant increased risk of major and minor bleeding compared to each agent alone.4-6 In contrast, the use of fish oil in conjunction with aspirin and clopidogrel in patients with cardiovascular disease followed for an average of 33 months has been shown to have no significant effect on risk of major and minor bleeding compared to those on aspirin and clopidogrel alone, with a trend toward a reduced risk of minor bleeding in those taking fish oil.4 In Preliminary Data it is shown that a robust synergistic effect between Lovaza® and aspirin on the downregulation of platelet function may occur. These data suggest that the most potent omega-3 fatty acids found in fish oil (eicosapentaenoic acid {EPA} and docosahexaenoic acid {DHA}) act acutely to modulate a major contributor to the pathophysiology of acute coronary syndromes. This study will randomize 60 patients with ST elevation myocardial infarction to treatment with Lovaza® or placebo and measure the differences in platelet function and electrophysiologic parameters between treatment arms during their acute hospitalization and 1 week after discharge.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Myocardial Infarction
  • Drug: Lovaza®
    Lovaza® is prescription grade EPA+DHA fish oil supplement.
    Other Name: Fish oil
  • Drug: The placebo contained 1 gram of corn oil in each capsule.
    Placebo Pill
    Other Name: Corn oil
  • Experimental: Lovaza®
    Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
    Intervention: Drug: Lovaza®
  • Placebo Comparator: Corn Oil
    The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
    Intervention: Drug: The placebo contained 1 gram of corn oil in each capsule.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
4
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Acute myocardial infarction documented by at least 2 of the following:

    1. Typical symptoms
    2. Abnormal levels of cardiac biomarkers (troponin I or T or CK-MB mass) with at least one determination > 99th percentile or ULN for the laboratory
    3. ECG findings diagnostic of myocardial infarction based on the American College of Cardiology criteria.
  • Status-post urgent or emergent PCI
  • Have a Thrombolysis In Myocardial Infarction (TIMI) flow grade = 3 (complete perfusion) post PCI.
  • Have the capacity for informed consent (e.g. without significant dementia or sedation from medication)
  • Ingested 325 mg of chewed aspirin as part of the acute coronary syndrome treatment protocol.

Exclusion Criteria:

  • No informed consent
  • Daily aspirin use prior to index hospitalization
  • Known prior myocardial infarction
  • Known pregnancy
  • Known allergy to fish, fish oil, or aspirin
  • Known active internal or non-superficial bleeding, known bleeding disorder, coagulation defect, or thrombocytopenia
  • Thrombolysis in the past 12 hours
  • Treatment with a IIbIIIa inhibitor during index hospitalization
  • Cardiogenic shock or symptomatic hypotension or sitting SBP < 95 mmHg
  • Severe uncontrolled hypertension (≥180/110) or hypertensive retinopathy
  • A history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal (not hemorrhoidal) or genitourinary bleeding in the past 6 weeks
  • A history of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
  • A known arteriovenous malformation or aneurysm
  • Severe liver insufficiency (ALT ≥ 3 times normal)
  • Renal insufficiency requiring dialysis
  • A known diagnosis of vasculitis
  • Participation in another clinical study
  • History of malignancy, except subjects who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma
  • Oral contraceptive use
  • Daily use of NSAIDs
  • History of drug or alcohol abuse, or current weekly alcohol consumption >14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 shot of alcohol)
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01155336
LVZ114193
Yes
Robert Block, University of Rochester
University of Rochester
  • GlaxoSmithKline
  • Albany College of Pharmacy and Health Sciences
Principal Investigator: Robert Block, MD, MPH University or Rochester
University of Rochester
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP